Abstract

RAMOS-PENAFIEL, Christian Omar et al. Options for the Treatment of Acute Lymphoblastic Leukemia relapse. Review. Medicas UIS [online]. 2024, vol.37, n.1, pp.95-109.  Epub Mar 30, 2024. ISSN 0121-0319.  https://doi.org/10.18273/revmed.v37n1-2024008.

Acute lymphoblastic leukemia is a common type of cancer in children and young adults, and its treatment involves the use of chemotherapy and other drugs. However, many people relapse despite high initial remission rates, and long-term survival is poor. This study sought to explore the treatments used in cases of recurrent acute lymphoblastic leukemia and their applicability worldwide. A comprehensive review of retrospective and prospective studies published between 2012 and 2022 in medical databases was performed. The most common treatments for recurrent acute lymphoblastic leukemia include chemotherapy combinations, such as fludarabine, cytarabine, and mitoxantrone therapy. More intensive induction schemes, such as HyperCVAD, have also been used. However, there is little experience with other drugs, such as proteasome inhibitors and hypomethylating agents.

Keywords : T and B cell Acute Lymphoblastic Leukemia; Local relapse neoplasia; Chemotherapy; Immunotherapy.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )